Author

Emily R. James

University of CambridgeORCID 0000-0001-9731-5508Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Jamie D. MatthewsiD· 2 shared Lukas KenneriD· 2 shared Michaela SchledereriD· 2 shared Suzanne Dawn TurneriD· 2 shared Bengt HallbergiD· 1 shared Carla Vazquez Amos· 1 shared Charlotte Barrett· 1 shared Chenqu SuoiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jamie D. MatthewsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 30, 2026

Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas

Ruoyan Li, Jamie D. Matthews, Emily R. James…·Suzanne Dawn Turner

This study uses single-cell transcriptomics to analyze T cell lymphomas, identifies developmental origins, and discovers SYK and TIM3 as potential therapeutic targets.

DOI 10.64898/2026.03.27.714741

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 5, 2024

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

Perla Pucci, Charlotte Barrett, Ricky M. Trigg…·Suzanne Dawn Turner

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

1 citation

humangenetic perturbation / CRISPR

𝕏 PostBluesky